Hospital
Enumclaw Regional Hospital Association
Enumclaw Regional Hospital Association was paid $23.15M by Medicaid between Jan 2018 and Dec 2024, across 118 billing codes. Its largest line is 99284, emergency room visit (serious) — 19% of everything it billed.
33Billing provider infoENUMCLAW REGIONAL HOSPITAL ASSOCIATION
ENUMCLAW, WA 98022
ENUMCLAW, WA 98022
33aNPI1073674040assigned 12/13/2006
33bProvider typeCritical Access Hospital
28Total paid$23.15M
24GClaims217,817
24DCodes billed118
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Washington
Rank by total paid#7 of 30
Median peer was paid$9.10M
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36,038 | $4.06M | |
| 2019 | 35,942 | $3.61M | |
| 2020 | 25,454 | $2.51M | |
| 2021 | 29,813 | $2.65M | |
| 2022 | 32,248 | $3.43M | |
| 2023 | 33,725 | $3.79M | |
| 2024incomplete | 24,597 | $3.10M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 9,309 | 8,395 | $4.36M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 5,404 | 4,814 | $4.30M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 11,216 | 10,423 | $3.48M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 6.1% | 1,967 | 1,835 | $1.42M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.9% | 2,101 | 1,992 | $1.14M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 3.4% | 1,315 | 1,228 | $777K |
| J2704 | Injection, propofol, 10 mg | 2.9% | 6,696 | 3,754 | $669K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.9% | 4,049 | 3,829 | $667K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2.2% | 5,005 | 2,755 | $501K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.0% | 5,386 | 4,382 | $464K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.7% | 6,375 | 5,487 | $384K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 1,729 | 1,602 | $301K |
106 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 5,668 | $273K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.0% | 3,369 | $234K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,659 | $224K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,624 | $220K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,595 | $209K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,442 | $203K |
| 80053 | Comprehensive metabolic panel | <1% | 9,169 | $195K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,040 | $182K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,924 | $181K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 472 | $177K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,065 | $164K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,831 | $162K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,693 | $138K |
| 84484 | <1% | 5,016 | $133K | |
| 96376 | <1% | 2,356 | $113K | |
| 83690 | <1% | 5,413 | $110K | |
| G0378 | Hospital observation service, per hour | <1% | 187 | $103K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 328 | $100K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 678 | $84K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,113 | $83K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,989 | $77K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,877 | $68K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,433 | $66K |
| 83880 | <1% | 2,121 | $61K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,221 | $53K |
| 85610 | <1% | 5,422 | $51K | |
| 83605 | <1% | 2,724 | $50K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,308 | $45K |
| 87040 | <1% | 2,321 | $42K | |
| 81001 | <1% | 4,498 | $40K | |
| 84703 | <1% | 2,046 | $37K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 526 | $37K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 135 | $37K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,689 | $37K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,259 | $36K |
| 81025 | <1% | 1,810 | $35K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,942 | $33K |
| 85379 | <1% | 956 | $32K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,746 | $31K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 332 | $30K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,738 | $30K |
| 80076 | <1% | 2,100 | $28K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,942 | $27K |
| 82962 | <1% | 2,665 | $27K | |
| 81003 | <1% | 2,658 | $25K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,916 | $24K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 258 | $23K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 308 | $23K |
| 80143 | <1% | 698 | $23K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,567 | $22K |
| 80179 | <1% | 652 | $21K | |
| 84145 | <1% | 997 | $17K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 952 | $16K |
| 76830 | Ultrasound, transvaginal | <1% | 166 | $16K |
| 87070 | <1% | 621 | $15K | |
| 76801 | <1% | 155 | $15K | |
| 84702 | <1% | 311 | $14K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,479 | $13K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 795 | $12K |
| 85027 | <1% | 985 | $12K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 27 | $8K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 447 | $7K |
| 87186 | <1% | 450 | $7K | |
| 83735 | <1% | 635 | $7K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 245 | $5K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 88 | $4K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 189 | $4K |
| 80047 | <1% | 114 | $4K | |
| 87430 | <1% | 279 | $4K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 41 | $4K |
| 73610 | <1% | 82 | $4K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 189 | $4K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,324 | $4K |
| 74018 | <1% | 85 | $3K | |
| 73630 | <1% | 54 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 12 | $3K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 114 | $2K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 230 | $2K |
| 73130 | <1% | 40 | $2K | |
| 12001 | <1% | 14 | $2K | |
| 81002 | <1% | 180 | $2K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 31 | $2K |
| 12011 | <1% | 12 | $2K | |
| 82803 | <1% | 31 | $2K | |
| 90715 | <1% | 40 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 25 | $1K |
| 88342 | <1% | 16 | $1K | |
| A9270 | Non-covered item or service | <1% | 5,357 | $1K |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 67 | $857.05 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 13 | $753.21 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 34 | $698.47 |
| 82550 | <1% | 75 | $662.73 | |
| 87428 | <1% | 16 | $460.00 | |
| 82247 | <1% | 47 | $415.98 | |
| 87205 | <1% | 29 | $401.15 | |
| 82040 | <1% | 44 | $349.98 | |
| 84450 | <1% | 52 | $307.75 | |
| 84460 | <1% | 50 | $296.87 | |
| 84155 | <1% | 44 | $258.99 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 15 | $235.07 |
| 84075 | <1% | 44 | $220.89 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 16 | $210.71 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 56 | $179.97 |
| 0240U | <1% | 297 | $29.98 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 14 | $28.90 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 41 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFITZGERALD, MIKE (CFO)
| Provider | Location | Paid |
|---|---|---|
| Saint Clare Hospital | Lakewood, WA | $30.09M |
| FHS Inpatient Team | Tacoma, WA | $323K |
| FHS Inpatient Team | Lakewood, WA | $301K |
| FHS Inpatient Team | Federal Way, WA | $181K |
| Franciscan Health System | Tacoma, WA | $85K |
| United States Catholic Conference | Federal Way, WA | $43K |
| FHS Inpatient Team | Gig Harbor, WA | $27K |
| Franciscan Medical Group | Silverdale, WA | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.